4results about How to "Short modeling cycle" patented technology

The invention relates to the field of zebra fish screening (evaluation) models, and discloses a method for establishing an intestinal dysfunction model by using zebra fish, which comprises the following steps: (1-1) selecting zebra fish greater than 5dpf and feeding the zebra fish in zebra fish culture water at the culture temperature of 26-30 DEG C; and (1-2) injecting different doses of escherichia coli into intestinal tracts of the zebrafish in the model experiment group, and constructing a zebrafish intestinal dysfunction model group. According to the method, escherichia coli cells are directly injected into the intestinal tract of the zebra fish by utilizing a microinjection technology for the first time, so that the sepsis-induced intestinal dysfunction model is established, the model is closer to the actual infection condition, and a more comprehensive and complex sepsis pathological process can be simulated. According to the method, the high-accuracy, scientific and reasonable zebra fish intestinal dysfunction model is successfully constructed by optimizing influence factors such as modeling concentration, evaluation indexes and multi-index verification selection. Compared with other methods, the model has the advantage of short modeling period, so that the detection cost is greatly reduced, and wide popularization and application are facilitated.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

The invention belongs to the field of biological medicine, and provides application of a CYTB-187AA protein activator in preparation of a medicine for preventing and / or treating chronic obstructive pulmonary disease. Research results show that the progress of the chronic obstructive pulmonary disease can be effectively inhibited by increasing CYTB-187AA protein expression and / or improving activity, so that the purpose of prevention or treatment is achieved, and the application of the CYTB-187AA protein activator in preparation of the medicine for preventing and / or treating the chronic obstructive pulmonary disease is promoted. The research result of the invention is of great significance to scientific research and clinical treatment of chronic obstructive pulmonary disease.